Morningstar
•
Jul 15, 2026
Biogen Inc.: Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Summary
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Illumina Inc
Sep 03, 2026
•
ILMN
Market Digest: ILMN, SLF, PANW, AXON
Sep 03, 2026
•
ILMN, AXON, SLF, PANW
BMRN: Lowering target price to $71.00
Sep 02, 2026
•
BMRN
Market Update: MRVL, GSK, MET
Sep 01, 2026
•
MET, GSK, MRVL
Analyst Report: GSK PLC
Sep 01, 2026
•
GSK
